A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Candidemia
Phase: N/A
Status: Completed
Sponsored by: Merck Sharp & Dohme Corp.
Summary
This study will evaluate the incidence rate of Candida blood stream infection (candidemia)
among people hospitalized in participating medical centers in Brazil, and will assess the
antifungal drug susceptibility patterns of Candida clinical isolates. No hypotheses will be
tested in the study. Candida blood stream isolates collected from people hospitalized for
any reason during the study period will be sent to a core mycology laboratory for antifungal
drug susceptibility testing. All people who develop candidemia while hospitalized will be
considered participants in the study.
Clinical Details
Official title: Brazilian Network of Candidemia: a Laboratory-based Surveillance Study on Candida Bloodstream Infections in 10 Medical Centers
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: Number of participants with Candidemia per 1000 hospital admissionsNumber of participants with Candidemia per 1000 patient-Days in hospital Percentage of Specific Candida Isolates Susceptible to Amphotericin B, Fluconazole, Voriconazole, Anidulafungin, and Caspofungin
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hospitalized in a participating medical center
- Developed candidemia blood stream infection (confirmed by isolation of Candida
species from blood culture)
Locations and Contacts
Additional Information
Starting date: April 2010
Last updated: October 30, 2014
|
